Quantum Genomics (Alternext – FR0011648971 – ALQGC), a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, has just met in Paris. At that meeting, the Advisory Board reviewed the various investigations under way and recommended future development directions and stages.
Pierre Corvol, Chairman of Quantum Genomics’ Scientific Advisory Board, said:
“This latest meeting of the Scientific Advisory Board has been especially productive and offers further prospects for developing a range of drug programs, particularly by broadening the upcoming clinical trials in Europe and the United States using a multicentric approach.”
[button link=”http://www.quantum-genomics.com/www/wp-content/uploads/2015/11/QGC_PR_SAB-MEETING-20151125_EN.pdf” target=”_blank” title=”Download Press Release” size=”small” color=”red”]